blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3288568

EP3288568 - SECRETORY TNT CAR CELL IMMUNOTHERAPY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  11.12.2020
Database last updated on 11.09.2024
FormerExamination is in progress
Status updated on  18.01.2020
FormerRequest for examination was made
Status updated on  02.02.2018
FormerThe international publication has been made
Status updated on  04.11.2016
Most recent event   Tooltip11.12.2020Application deemed to be withdrawnpublished on 13.01.2021  [2021/02]
Applicant(s)For all designated states
University of Southern California
1150 South Olive Street, Suite 2300
Los Angeles, CA 90015 / US
[2018/10]
Inventor(s)01 / EPSTEIN, Alan L.
c/o University of Southern California
1150 South Olive Street Suite 2300
Los Angeles, California 90015 / US
02 / KASLOW, Harvey
c/o University of Southern California
1150 South Olive Street Suite 2300
Los Angeles, California 90015 / US
03 / HU, Peisheng
c/o University of Southern California
1150 South Olive Street Suite 2300
Los Angeles, California 90015 / US
 [2018/10]
Representative(s)Tomkins & Co
5 Dartmouth Road
Dublin 6 / IE
[2018/10]
Application number, filing date16787271.229.04.2016
[2018/10]
WO2016US30248
Priority number, dateUS201562155296P30.04.2015         Original published format: US 201562155296 P
[2018/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016176639
Date:03.11.2016
Language:EN
[2016/44]
Type: A1 Application with search report 
No.:EP3288568
Date:07.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2016 takes the place of the publication of the European patent application.
[2018/10]
Search report(s)International search report - published on:US03.11.2016
(Supplementary) European search report - dispatched on:EP03.12.2018
ClassificationIPC:A61K35/17, A61K39/395, C12N15/00
[2018/10]
CPC:
C07K16/30 (EP,US); C07K16/18 (US); A61K35/17 (US);
A61K35/76 (EP,US); A61K38/177 (EP,US); A61K38/1774 (EP,US);
A61K38/193 (EP,US); A61K38/195 (EP,US); A61K38/20 (EP,US);
A61K38/2013 (EP,US); A61K38/208 (EP,US); A61K38/2086 (EP,US);
A61K39/3955 (US); A61K39/4611 (EP); A61K39/4631 (EP);
A61K39/464412 (EP); A61K39/464438 (EP); A61K39/464452 (EP);
A61K45/06 (US); A61P35/00 (EP); A61P35/02 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P7/00 (EP);
C07K14/4748 (US); C07K14/521 (US); C07K14/535 (US);
C07K14/54 (US); C07K14/5434 (US); C07K14/5443 (US);
C07K14/55 (US); C07K14/7051 (US); C07K14/70517 (US);
C07K14/70521 (US); C07K14/70532 (US); C07K14/70575 (US);
C07K14/70578 (US); A61K2039/5158 (US); A61K2039/5256 (US);
A61K2039/572 (US); A61K35/761 (EP,US); A61K38/00 (EP,US);
C07K2317/24 (EP,US); C07K2317/53 (US); C07K2317/56 (US);
C07K2317/565 (US); C07K2317/622 (EP,US); C07K2317/73 (US);
C07K2317/76 (US); C07K2319/30 (US); C07K2319/33 (EP,US);
C07K2319/40 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/10]
TitleGerman:SEKRETORISCHE TNT-CAR-ZELLIMMUNTHERAPIE[2018/10]
English:SECRETORY TNT CAR CELL IMMUNOTHERAPY[2018/10]
French:IMMUNOTHÉRAPIE PAR CELLULES CAR TNT SÉCRÉTOIRES[2018/10]
Entry into regional phase02.11.2017National basic fee paid 
02.11.2017Search fee paid 
02.11.2017Designation fee(s) paid 
02.11.2017Examination fee paid 
Examination procedure02.11.2017Examination requested  [2018/10]
02.11.2017Date on which the examining division has become responsible
25.06.2019Amendment by applicant (claims and/or description)
22.01.2020Despatch of a communication from the examining division (Time limit: M06)
04.08.2020Application deemed to be withdrawn, date of legal effect  [2021/02]
03.09.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/02]
Fees paidRenewal fee
11.04.2018Renewal fee patent year 03
30.04.2019Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.04.202005   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2013287748  (JUNE CARL H [US], et al) [Y] 1-14 * page 0017, paragraph 0019 * * paragraph [0301] - paragraph [0302] *;
 [Y]  - MILLER G K ET AL, "Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (19931201), vol. 12, no. 6, ISSN 0272-457X, pages 689 - 698, XP002119491 [Y] 1-14 * abstract *
 [Y]  - HORNICK J L ET AL, "A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, LIEBERT, US, (19980101), vol. 13, no. 4, pages 255 - 268, XP002119496 [Y] 1-14 * abstract *
 [Y]  - KHAWLI L A ET AL, "NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050101), vol. 11, no. 8, doi:10.1158/1078-0432.CCR-04-2310, ISSN 1078-0432, pages 3084 - 3093, XP003016188 [Y] 1-14 * abstract * * First full paragraph; page 3085 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-2310
International search[Y]US6827925  (WILLIAMS ANDREW JAMES [GB], et al) [Y] 1-4, 101, 102 * . Especially col 1 ln 66 continued to col 2 ln 12; col 2 ln 15-19, col 2 ln 20-26, col 3 ln 66 continued to col 4 ln 11 *;
 [Y]US2013287748  (JUNE CARL H [US], et al) [Y] 1-4, 101, 102 * . Especially para [0008], [0090] *;
 [A]  - MILLER et al., "Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones.", Hybridoma, (19931200), vol. 12, no. 6, pages 689 - 698, XP002119491 [A] 1-4 * . Especially abstract. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.